Environmental and genetic modifiers of the progression to fibrosis and cirrhosis in hemochromatosis

Blood

Volumn 111, Issue 9, 2008, Pages 4456-4462

  Wood, Marnie J ^a,c   Powell, Lawrie W ^a,c   Ramm, Grant A ^a,b,d  

^a Medical Research   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c Women's Hospital Radiology Department   (Australia)

^d Queensland Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA 1 ANTITRYPSIN; ANGIOTENSINOGEN; BONE MORPHOGENETIC PROTEIN; CERULOPLASMIN; GLUTATHIONE TRANSFERASE P1; HEMOJUVELIN; HEPCIDIN; INTERFERON; INTERLEUKIN 6; IRON; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; PROTON PUMP INHIBITOR; RIBAVIRIN; TANNIN; TRANSFERRIN RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALCOHOL CONSUMPTION; ARTICLE; BLOOD DONOR; CYTOKINE PRODUCTION; DIETARY INTAKE; DISEASE COURSE; DISEASE SEVERITY; DNA MODIFICATION; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; FATTY LIVER; FIBROGENESIS; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HEMOCHROMATOSIS; HEPATITIS C; HUMAN; IRON INTAKE; IRON OVERLOAD; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER LEVEL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH ACID SECRETION; VIRUS HEPATITIS; FIBROSIS; REVIEW; RISK FACTOR;

DISEASE PROGRESSION; FIBROSIS; HEMOCHROMATOSIS; HUMANS; LIVER CIRRHOSIS; RISK FACTORS;

EID: 47149091490     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-122374     Document Type: Article

References (85)

1. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ, Global prevalence of putative haemochromatosis mutations. J Med Genet. 1997;34:275-278.
2. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class Hike gene is mutated in patients with hereditary haemochromatosis. Nat Genet. 1996; 13:399-408.
3. Allen KJ, Gurrin LC, Constantine CC, et al. Ironoverload-related disease in HFE hereditary hemochromatosis. N Engl J Med. 2008;358:221-230.
4. Strohmeyer G, Niederau C, Stremmel W. Survival and causes of death in hemochromatosis: observations in 163 patients. Ann N YAcad Sci. 1988; 526:245-257.
5. Adams PC, Reboussin DM. Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005; 352:1769-1778.
6. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G-> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet. 2002;359:211-218.
7. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999;341:718-724.
8. Phatak PD. Ryan DH. Cappuccio J. et al. Prevalence and penetrance of HFE mutations in 4865 unselected primary care patients. Blood Cells Mol Dis. 2002;29:41-47.
9. Powell LW. Dixon JL. Ramm GA, et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch Intern Med. 2006;166:294-301.
10. Bacon BR. Olynyk JK. Brunt EM, Britton RS, Wolff RK. HFE Genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med. 1999;130:953-962.
11. Tavill AS, American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association. Diagnosis and management of hemochromatosis. Hepatology. 2001;33:1321-1328.
12. Asberg A, Hveem K, Thorstensen K, et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65, 238 persons. Scand J Gastroenterol. 2001;36:1108-1115.
13. Fracanzani AL, Fargion S, Romano R, et al. Portal hypertension and iron depletion in patients with genetic hemochromatosis. Hepatology. 1995;22:1127-1131.
14. Beaton MD, Adams PC. Prognostic factors and survival in patients with hereditary hemochromatosis and cirrhosis. Can J Gastroenterol. 2006;20:257-260.
15. Adams PC. Is there a threshold of hepatic iron concentration that leads to cirrhosis in C282Y hemochromatosis? Am J Gastroenterol. 2001;96:567-569.
16. Olynyk JK, St Pierre TG, Britton RS, Brunt EM, Bacon BR. Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging. Am J Gastroenterol. 2005; 100:837-841.
17. Hutchinson C, Geissler C, Powell J, Bomford A. Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut. 2007;56:1291-1295.
18. Kaltwasser JP, Werner E, Schalk K, Hansen C, Gottschalk R, Seidl C. Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis. Gut. 1998;43:699-704.
19. Cade JE, Moreton JA, O'Hara B, et al. Diet and genetic factors associated with iron status in middle-aged women. Am J Clin Nutr. 2005;82:813-820.
20. Barton JC, Preston BL, McDonnell SM, Rothenberg BE. Severity of iron overload in hemochromatosis: effect of volunteer blood donation before diagnosis. Transfusion. 2001;41:123-129.
21. Harrison-Findik DD, Schafer D, Klein E, et al. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem. 2006;281:22974-22982.
22. Bridle KR, Cheung T-K, Murphy TL, et al. Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin Exp Res. 2006;30:106-112.
23. Moirand R, Adams PC. Bicheler V, Brissot P, Deugnier Y. Clinical features of genetic hemochromatosis in women compared with men. Ann Intern Med. 1997;127:105-110.
24. Deugnier Y, Jouanolle A-M, Chaperon J, et al. Gender-specific phenotypic expression and screening strategies in C282Y-linked haemochromatosis: a study of 9396 French people. Br J Haematol. 2002;118:1170-1178.
25. Pratiwi R. Fletcher LM, Pyper WR. et al. Linkage disequilibrium analysis in Australian haemochromatosis patients indicates bipartite association with clinical expression. J Hepatol. 1999;31:39-46.
26. *07 in hemochromatosis probands with HFE C282Y homozygosity: frequency disparity in men and women and lack of association with severity of iron overload. Blood Cells Mol Dis. 2005;34:38-47.
27. Cruz E, Melo G, Lacerda R, Almeida S, Porto G. The CD8+ T-lymphocyte profile as a modifier of iron overload in HFE hemochromatosis: an update of clinical and immunological data from 70 C282Y homozygous subjects. Blood Cells Mol Dis. 2006;37:33-39.
28. Rivers CA. Barton JC, Gordeuk VR, et al. Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Blood Cells Mol Dis. 2007;38:247-252.
29. Wang F, Paradkar PN, Custodio AO, et al. Genetic variation in Mon1 a affects protein trafficking and modifies macrophage iron loading in mice. Nat Genet. 2007;39:1025-1032.
30. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090-2093.
31. Darshan D, Anderson GJ. Liver-gut axis in the regulation of iron homeostasis. World J Gastroenterol. 2007;13:4737-4745.
32. Zhang A-S, Anderson SA, Meyers KR, Hernandez C, Eisenstein RS, Enns CA. Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin. J Biol Chem. 2007;282:12547-12556.
33. Jacolot S, Le Gac G, Scotet V, Quere I, Mura C, Ferec C. HAM P as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood. 2004;103:2835-2840.
34. Merryweather-Clarke AT, Cadet E, Bomford A. et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet. 2003;12:2241-2247.
35. Le Gac G, Scotet V, Ka C, et al. The recently identified type 2Ajuvenile haemochromatosis gene (HJV). a second candidate modifier of the C282Y homozygous phenotype. Hum Mol Genet. 2004;13:1913-1918.
36. Milet J, Dhais V, Bourgain C, et al. Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE hemochromatosis penetrance. Am J Hum Genet. 2007;81:799-807.
37. Gouya L, Muzeau F, Robreau A-M, et al. Genetic study of variation in normal mouse iron homeostasis reveals ceruloplasmin as an HFE-hemochromatosis modifier gene. Gastroenterology. 2007;132:679-686.
38. Levy JE, Montross LK, Andrews NC. Genes that modify the hemochromatosis phenotype in mice. J Clin Invest. 2000;105:1209-1216.
39. Oates PS. The relevance of the intestinal crypt and enterocyte in regulating iron absorption. Pflugers Arch. 2007:455:201-213.
40. Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DHG. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology. 2002;122:281-289.
41. Adams PC, Agnew S. Alcoholism in hereditary hemochromatosis revisited: prevalence and clinical consequences among homozygous siblings. Hepatology. 1996;23:724-727.
42. Scotet V, Merour M-C, Mercier A-Y. et al. Hereditary hemochromatosis: effect of excessive alcohol consumption on disease expression in patients homozygous for the C282Y mutation. Am J Epidemiol. 2003;158:129-134.
43. Tsukamoto H, Home W, Kamimura S, et al. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest. 1995;96:620-630.
44. Grundy SM, Brewer HB Jr, Cleeman Jl, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-438.
45. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917-923.
46. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130:1636-1642.
47. Powell EE, Ali A, Clouston AD, et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology. 2005;129:1937-1943.
48. Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology. 2002;122:931-939.
49. Valenti L, Fracanzani AL, Dongiovanni P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol. 2007; 102:1251-1258.
50. Tung BY. Emond MJ, Bronner MP, Raaka SD, Cotler SJ, Kowdley KV. Hepatitis C, iron status, and disease severity: Relationship with HFE mutations. Gastroenterology. 2003;124:318-326.
51. Fujita N, Sugimoto R, Urawa N, et al. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C. J Gastroenterol Hepatol. 2007;22:1886-1893.
52. Mummadi R, Kasturi K, Sood G. Iron depletion and response to interferon in chronic hepatitis C: a meta-analysis [abstract]. Hepatology. 2007;46:365A.
53. Diwakaran HH, Befeler AS, Britton RS, Brunt EM, Bacon BR. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J Hepatol. 2002; 36:687-691.
54. Adams PC, Passmore L, Chakrabarti S, et al. Liver diseases in the hemochromatosis and iron overload screening study. Clin Gastroenterol Hepatol. 2006;4:918-923.
55. Fargion S, Bissoli F, Fracanzani AL, et al. No association between genetic hemochromatosis and alpha1-antitrypsin deficiency. Hepatology. 1996; 24:1161-1164.
56. Osterreicher CH, Datz C, Stickel F, et al. TGF-betai codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. Cytokine. 2005;31:142-148.
57. Distante S, Elmberg M, Foss Haug KB. et al. Tumour necrosis factor alpha and its promoter polymorphisms' role in the phenotypic expression of hemochromatosis. Scand J Gastroenterol. 2003; 38:871-877.
58. Fargion S, Valenti L, Dongiovanni P, et al. Tumor necrosis factor alpha promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood. 2001;97:3707-3712.
59. Beutler E, Gelbart T. Tumor necrosis factor alpha promoter polymorphisms and liver abnormalities of homozygotes for the 845G>A (C282Y) hereditary hemochromatosis mutation. Blood. 2002; 100:2268-2269.
60. Stickel F, Osterreicher CH, Datz C, et al. Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. Arch Intern Med. 2005;165:1835-1840.
61. Osterreicher CH, Datz C, Stickel F, et al. Association of myeloperoxidase promotor polymorphism with cirrhosis in patients with hereditary hemochromatosis. J Hepatol. 2005;42:914-919.
62. Muhlbauer M, Bosserhoff AK, Hartmann A, et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology. 2003;125:1085-1093.
63. Glas J, Török Torok H-P, Tonenchi L, Schiemann U, Folwaczny C. The 2518 promotor polymorphism in the MCP-1 gene is not associated with liver cirrhosis in chronic hepatitis C virus infection. Gastroenterology. 2004;126:1930-1931.
64. Hellier S, Frodsham AJ, Hennig BJW, et al. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology. 2003;38:1468-1476.
65. Loreal O, Deugnier Y. Moirand R, et al. Liverfibrosis in genetic hemochromatosis: respective roles of iron and non-iron-related factors in 127 homozygous patients. J Hepatol. 1992;16:122-127.
66. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C: The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997; 349:825-832.
67. Di Martino V, Lebray P, Myers RP, et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology. 2004;40:1426-1433.
68. Shimizu I. Impact of oestrogens on the progression of liver disease. Liver Int. 2003;23:63-69.
69. Czaja MJ, Weiner FR, Flanders KC, et al. In vitro and in vivo association of transforming growth factor-beta 1 with hepatic fibrosis. J Cell Biol. 1989;108:2477-2482.
70. Hellerbrand C, Stefanovic B, Giordano F, Burchardt ER, Brenner DA. The role of TGF[beta]1 in initiating hepatic stellate cell activation in vivo. J Hepatol. 1999;30:77-87.
71. Gewaltig J, Mangasser-Stephan K, Gartung C, Biesterfeld S, Gressner AM. Association of polymorphisms of the transforming growth factor-[beta]1 gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta. 2002;316:83-94.
72. Powell EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology. 2000;31:828-833.
73. Tag CG, Mengsteab S, Hellerbrand C, Lammert F, Gressner AM, Weiskirchen R. Analysis of the transforming growth factor-[beta]1 (TGF-[beta]1) codon 25 gene polymorphism by Light Cycleranalysis in patients with chronic hepatitis C infection. Cytokine. 2003;24:173-181.
74. Yee LJ, Tang J, Herrera J, Kaslow RA, van Leeuwen DJ. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun. 2000;1:386-390.
75. Pereira RM, dos Santos RAS, Teixeira MM, et al. The renin-angiotensin system in a rat model of hepatic fibrosis: evidence for a protective role of angiotensin-(1-7). J Hepatol. 2007;46:674-681.
76. Friedman SL. Hepatic stellate cells. Prog Liver Dis. 1996;14:101-130.
77. Marra F, DeFranco Ft. Grappone C, et al. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol. 1998;152:423-430.
78. Marra F. Romanelli HG, Giannini C, et al. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology. 1999;29:140-148.
79. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun. 1999;259:344-348.
80. Ramm GA, Ruddell RG. Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Semin Liver Dis. 2005:25:433-449.
81. Hayes JD. Strange RC. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology. 2000;61:154-166.
82. Ali-Osman F, Akande O, Antoun G, Mao JX, Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants: evidence for differential catalytic activity of the encoded proteins. J Biol Chem. 1997;272:10004-10012.
83. Ghobadloo SM, Yaghmaei B, Bakayev V, et al. GSTPI. GSTMI, and GSTTI genetic polymorphisms in patients with cryptogenic liver cirrhosis. J Gastrointest Surg. 2004;8:423-427.
84. Winterbourn CC, Vissers MC, Kettle AJ. Myeloperoxidase. Curr Opin Hematol. 2000;7:53-58.
85. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem. 1996;271:14412-14420.